Los Gatos, CA, March 4, 2026 – At their February meeting, the American Medical Association (AMA) CPT® Editorial Panel voted to extend the Category III code applicable to the Orlucent® Skin Fluorescent Imaging (SFI) system. Category III codes are designed for emerging technologies and can be established before FDA clearance is granted. In requesting the extension, Orlucent was able to demonstrate ongoing clinical research and compelling results for the SFI system. With the extension, Orlucent is well positioned to seek coverage and payment for its system upon commercialization. 0700T – Molecular fluorescent imaging of suspicious nevus; first lesion; 0701T – Molecular fluorescent imaging of suspicious nevus; each additional lesion